NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) Stock Forecast, Price & News

$11.73

-0.11 (-0.93%)

(As of 10:08 AM ET)

Compare

Today's Range: $11.68
▼
$11.91
50-Day Range: $11.81
▼
$18.49
52-Week Range: $6.58
▼
$26.49

Volume: 17,806 shs
Average Volume: 428,513 shs
Market Capitalization: $493.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.25

4D Molecular Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 206.2% Upside
$36.25 Price Target
Short Interest: Bearish
8.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.89) to ($3.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

929th out of 965 stocks

Biological Products, Except Diagnostic Industry

155th out of 156 stocks

3.3

Analyst's Opinion

Consensus Rating
4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.25, 4D Molecular Therapeutics has a forecasted upside of 206.2% from its current price of $11.84.
Amount of Analyst Coverage
4D Molecular Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.78% of the outstanding shares of 4D Molecular Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
4D Molecular Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in 4D Molecular Therapeutics has recently increased by 3.36%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
4D Molecular Therapeutics does not currently pay a dividend.
Dividend Growth
4D Molecular Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FDMT.

2.2

News and Social Media Coverage

News Sentiment
4D Molecular Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
MarketBeat Follows
Only 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 4D Molecular Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 4D Molecular Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
4D Molecular Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

FDMT Price History

30 days | 90 days | 365 days | Advanced Chart

FDMT Stock News Headlines

September 25, 2023 | msn.com

4D Molecular Therapeutics: Some Failures, A Few Key Successes

September 14, 2023 | finanznachrichten.de

4D Molecular Therapeutics, Inc.: 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 7, 2023 | finance.yahoo.com

4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD

September 7, 2023 | finance.yahoo.com

4DMT to Participate in Upcoming Investor Conferences

August 9, 2023 | finance.yahoo.com

4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights

August 9, 2023 | finance.yahoo.com

Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year

July 31, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

July 31, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)

July 29, 2023 | finance.yahoo.com

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

July 17, 2023 | finance.yahoo.com

4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data

July 14, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)

July 10, 2023 | seekingalpha.com

4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance

June 9, 2023 | msn.com

B of A Securities Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation

June 8, 2023 | markets.businessinsider.com

4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why

June 7, 2023 | finance.yahoo.com

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

June 7, 2023 | finance.yahoo.com

Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics

June 3, 2023 | morningstar.com

4D Molecular Therapeutics Inc Ordinary Shares

May 24, 2023 | finance.yahoo.com

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

May 24, 2023 | markets.businessinsider.com

4D Molecular Therapeutics (FDMT) Gets a Buy from BMO Capital

May 12, 2023 | finance.yahoo.com

Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics

May 11, 2023 | finance.yahoo.com

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 10, 2023 | finance.yahoo.com

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

May 9, 2023 | finance.yahoo.com

4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 8, 2023 | finance.yahoo.com

4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?

May 5, 2023 | seekingalpha.com

4D Molecular Therapeutics prices $120M share offering

See More Headlines

Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FDMT Company Calendar

Last Earnings: 8/09/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FDMT
CUSIP: N/A
CIK: 1650648
Web: www.4dmoleculartherapeutics.com
Phone: 510-505-2680
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $36.25
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +206.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-107,490,000.00
Net Margins: -4,876.01%
Pretax Margin: -4,876.01%
Return on Equity: -43.40%
Return on Assets: -39.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.11
Quick Ratio: 23.11

Sales & Book Value

Annual Sales: $3.13 million
Price / Sales: 159.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.14 per share
Price / Book: 1.66

Miscellaneous

Outstanding Shares: 42,050,000
Free Float: 37,553,000
Market Cap: $497.87 million
Optionable: Not Optionable
Beta: 2.44

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. John F. Milligan Ph.D. (Age 62)
Exec. Chairman
Comp: $150k

Dr. David H. Kirn M.D. (Age 61)
Co-Founder, CEO & Director
Comp: $920.97k

Dr. Fariborz Kamal Ph.D. (Age 60)
Pres & COO
Comp: $678.4k

Ms. Theresa Janke (Age 48)
Co-Founder & Chief of Staff

Mr. Uneek Mehra (Age 51)
Chief Financial & Bus. Officer

Mike Zanoni
VP of Investor Relations

Dr. Scott P. Bizily J.D. (Age 51)
Ph.D., Chief Legal & HR Officer and Corp. Sec.

Dr. Robert Y. Kim M.B.A. (Age 62)
M.D., Chief Medical Officer

Dr. An Song Ph.D.
Chief Devel. Officer

Ms. Karen S. Carothers (Age 72)
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FDMT Stock - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FDMT shares.
View FDMT analyst ratings or view top-rated stocks.
What is 4D Molecular Therapeutics' stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month price objectives for 4D Molecular Therapeutics' stock. Their FDMT share price forecasts range from $13.00 to $68.00. On average, they predict the company's share price to reach $36.25 in the next year. This suggests a possible upside of 206.2% from the stock's current price.
View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts.
How have FDMT shares performed in 2023?: 4D Molecular Therapeutics' stock was trading at $22.21 at the start of the year. Since then, FDMT shares have decreased by 46.7% and is now trading at $11.84.
View the best growth stocks for 2023 here.
When is 4D Molecular Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our FDMT earnings forecast.
How were 4D Molecular Therapeutics' earnings last quarter?: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.77) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.77). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.43 million. 4D Molecular Therapeutics had a negative net margin of 4,876.01% and a negative trailing twelve-month return on equity of 43.40%.
What ETFs hold 4D Molecular Therapeutics' stock?: ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did 4D Molecular Therapeutics IPO?: (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.
What is 4D Molecular Therapeutics' stock symbol?: 4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT."
How do I buy shares of 4D Molecular Therapeutics?: Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 4D Molecular Therapeutics' stock price today?: One share of FDMT stock can currently be purchased for approximately $11.84.
How much money does 4D Molecular Therapeutics make?: 4D Molecular Therapeutics (NASDAQ:FDMT) has a market capitalization of $497.87 million and generates $3.13 million in revenue each year. The company earns $-107,490,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.
How many employees does 4D Molecular Therapeutics have?: The company employs 137 workers across the globe.
How can I contact 4D Molecular Therapeutics?: The official website for the company is www.4dmoleculartherapeutics.com. The company can be reached via phone at 510-505-2680 or via email at mzanoni@4dmt.com.

This page (NASDAQ:FDMT) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial